“We realize, looking at the literature and also our clinical experience, that there are significant health disparities that are well documented in literature in Latinx and Hispanic rheumatoid arthritis patients, including perceptions of increased pain, fatigue, higher risk for depression, and a history of other self-help and self-management programs,” Adena Batterman, MSW, LCSW, explained.
Drs Nehad Soloman, Joy Schechtman, and Robert Levine share insights on how to measure treatment efficacy in the management of RA.
Rheumatology experts discuss the potential roadblocks to treatment of RA, such as insurance access.
Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.
Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.
Nehad Soloman, MD, discusses the impact of new biosimilars to become available in the U.S. in 2023 on rheumatic disease management.
Nehad Soloman, MD; Joy Schechtman, DO; and Robert Levine, MD, review how the increase in treatment options for RA has led to a trial-and-error approach to treatment.
Drs Nehad Soloman, Joy Schechtman, and Robert Levine describe the treatment path from conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to biologic or targeted disease-modifying antirheumatic drugs (b/tsDMARDs) for a typical rheumatoid arthritis (RA) patient.
Enrollment in clinical trials across all disease states, particularly in lupus, continues to be an ongoing challenge.
Investigators strive to learn more about whether mTORC1 inhibitors are a feasible approach for treating patients with systemic JIA.
“There’s still a great need for additional treatment for this very dangerous condition,” Pui Lee, MD, PhD, emphasized.
Tarun Sharma, MD, a rheumatologist with the Allegheny Health Network who helped author the American College of Rheumatology's most recent gout guidelines, sits down to provide perspective on the latest updates in gout from 2022, including new trial data, regulatory news and updates, and a glimpse into what he is most excited for in 2023.
Results indicated that vaccine response with the standard regimen dramatically low; however, both novel strategies were able to significantly improve response.
“These are people with autoimmune conditions who are taking immunomodulatory drugs that affect their immune system,” Mudano emphasized. “It's been shown that they may have worse outcomes if they do get COVID. So, it's important that they know that they really need this vaccine.”
Nowell emphasized that simple changes, such as targeted walking goals and meditative breathing, are low energy and low cost, yet extremely effective.
“There's a real interest and need for wellness programs out there among people living with psoriatic arthritis. This is something that matters to them even more now living with a chronic disease.”
Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.
Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.
“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."
Gout, if left untreated, can lead to flares that can increase the likelihood of depression and anxiety.
Wipfler emphasized that most of the delays have been associated with pharmacies needing to confirm the purpose of the prescription with the provider.
“We imagine that the rate of problems [accessing methotrexate] is going to be much higher in higher-risk populations," Wipfler explained.
Hamilton and his team aim to reduce intensive and often unnecessary screening, including weekly fetal cardiac ultrasounds, via autoantibody identification.
The number of autoantibodies and congenital heart block pregnancies expanded to approximately 30 different autoantibodies to different targets near term.
John Cush, MD, discusses his CCR West presentation “Rheumatology Year in Review: 2022.”
John Cush, MD, discusses his presentation “Rheumatoid Arthritis: How Early is Too Early to Diagnose and Treat?”
Dr. Veronica Anwuri discusses how apremilast (Otezla), the first oral, non biologic treatment option for plaque psoriasis can address the systemic pain associated with psoriatic arthritis.
Drs. Anne E. Winkler and Kristi V. Mizelle share practice pearls to optimize the management of patients of patients diagnosed with lupus.
Experts in rheumatology provide an overview of novel treatment options currently under investigation for the treatment of systemic lupus erythematosus and lupus nephritis.
Kristi V. Mizelle, MD, MPH, FACR comments on long term efficacy data on the use of biologics in lupus, with a focus on preventing organ damage.